Category: News

September is Blood Cancer Awareness Month, a time to raise awareness about the many ongoing efforts to fight blood cancer and to remember the hundreds of thousands of patients who have passed away due to these devastating conditions. Blood cancer encompasses disorders that affect the blood, bone marrow, and lymphatic system. Depending on the type of cells affected, these cancers are called leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. Someone in the U.S. dies from blood cancer every 9 minutes, and more than 1.5 million Americans are living with or in remission from blood cancer.

Blood cancer treatment usually starts with chemotherapy and can occur alone or with other drugs and treatments. Often, these treatments are designed to destroy the patient’s cancerous bone marrow. Other times, chemotherapy and radiation that kill circulating cancer cells in the blood also have an unfortunate side effect of destroying the patient’s bone marrow, where blood cells are made. The purpose of bone marrow transplants (also called hematopoietic stem cell transplants, or HSCT) is to replenish the body with new bone marrow. The new bone marrow will start producing healthy, cancer-free blood cells after a successful transplant. In some cases, the new blood cells will even attack and destroy cancer cells that survived the initial chemotherapy round, a phenomenon called the graft-versus-tumor effect. 

The best bone marrow transplant outcomes happen when a patient’s human leukocyte antigen (HLA) genes match that of their donor. For many patients, the best match is a sibling. However, only about 30% of patients have an HLA-matched sibling, which has led to the development of global bone marrow donor registries to facilitate the act of matching patients to unrelated donors with an ideal HLA. Despite the size of these registries, not all patients are able to find a suitable donor, and large variability in group representation has a particularly negative effect on minority populations. 

At Ossium, we are driven by the opportunity to impact patients in need and we believe that a healthier world is a better one. We are working hard to build a vast and diverse bank of on-demand bone marrow that will make bone marrow transplants available for more patients.

Since the beginning of the pandemic, our facility in Indianapolis has had business-critical employees onsite to keep our production and manufacturing operations running smoothly. As a science-based company, we have followed the latest data-backed policies and advisories of the CDC and local governments. We are proud of our team in Indianapolis for staying safe and healthy as they achieved many milestones over the past year.

Our San Francisco team switched to working remotely in March 2020 and continued working from home through the first half of 2021 as the company more than doubled in size. During that period, the team continued to push the company forward and was able to successfully close our Series B fundraising. As a company, we strongly believe in the value of an in-person work model and a community that is built on real-life human connections. We also believe that nothing is more important than the health and safety of our employees, our partners, and our communities. This meant that any potential return to the office had to be rooted in a science-based approach — we wanted to ensure all of our stakeholders felt comfortable, safe, and supported.

Thus, once the San Francisco team was 100% vaccinated and the data suggested more broadly that vaccination efforts were vastly decreasing the spread of COVID-19, we began to scout for a new space. After looking at more than a dozen offices around the city, we finally found a new place to call ‘home’. The beautiful brick building, formerly known as “The Barrel House”, is located in the heart of downtown San Francisco and at one time served as a wine warehouse, prohibition speakeasy, and most recently a concert hall where musicians and talented artists would come together over good food, drinks, and music. The 6,400 ft², three-story building offers plenty of space for the team to grow, be creative, and collaborate as we (re)adapt to an in-person model.

In celebration of the new office and return to in-person work, we hosted an office-warming party in mid-July with all San Francisco Ossies and their significant others. It was an extra-special event since for many it was the first opportunity to meet and get to know one another outside of Zoom. It was an amazing evening with lots of laughter, tasty hors d’oeuvres, and good company.

Later in July, we were lucky to host another dinner party as our Co-Founder and CEO, Kevin Caldwell, graciously invited the whole team to his humble home. This too was a wonderful opportunity for the San Francisco Ossies and their partners to bond over good food and drinks, and we even had Erik Woods, the Co-Founder & Chief Science Officer join us from Indianapolis.

Here at Ossium, we understand the importance of celebration and human connection. We look forward to many more opportunities to relish our achievements both big and small, and can’t wait to see how we continue to evolve as a company in the years to come.

ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, and Ossium Health, a therapeutics company harnessing the power of stem cell science to improve treatment for patients with blood and immune diseases, announced on April 21 a collaboration agreement to evaluate and advance opportunities to combine their capabilities to further the goal of improving human health.

The collaboration plans to evaluate and advance opportunities to employ adult stem cells from deceased donors from Ossium Health’s first-in-the-world bone marrow bank in conjunction with ExCellThera’s ECT-001 cell expansion and rejuvenation technology, comprised of the UM171 small molecule and an optimized culture system, to treat blood cancers, improve solid organ tolerization and repair damage from radiation.

Read the full Globe Newswire story here.

Kevin Caldwell, Ossium’s Co-Founder & CEO, was featured on the latest podcast from Flux. Kevin chats with Flux’s Alice Lloyd George about Ossium’s mission, the history of bone marrow transplants, and the future of medicine.

Co-Founder, President & CEO, Kevin Caldwell talks about the mission and inspiration of Ossium Health in a recent Venture Stories podcast hosted by Village Global.

Listen here!